203 related articles for article (PubMed ID: 20878668)
21. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
22. Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms.
Butturini E; Butera G; Pacchiana R; Carcereri de Prati A; Mariotto S; Donadelli M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831372
[TBL] [Abstract][Full Text] [Related]
23. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R; Nomura T; Anderson CW; Sakaguchi K
J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
[TBL] [Abstract][Full Text] [Related]
24. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".
Friedler A; DeDecker BS; Freund SM; Blair C; Rüdiger S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):187-96. PubMed ID: 14741214
[TBL] [Abstract][Full Text] [Related]
25. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
26. Regulation of DNA binding of p53 by its C-terminal domain.
Weinberg RL; Freund SM; Veprintsev DB; Bycroft M; Fersht AR
J Mol Biol; 2004 Sep; 342(3):801-11. PubMed ID: 15342238
[TBL] [Abstract][Full Text] [Related]
27. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
28. Thermodynamic stability of wild-type and mutant p53 core domain.
Bullock AN; Henckel J; DeDecker BS; Johnson CM; Nikolova PV; Proctor MR; Lane DP; Fersht AR
Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14338-42. PubMed ID: 9405613
[TBL] [Abstract][Full Text] [Related]
29. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
[TBL] [Abstract][Full Text] [Related]
30. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.
Ang HC; Joerger AC; Mayer S; Fersht AR
J Biol Chem; 2006 Aug; 281(31):21934-21941. PubMed ID: 16754663
[TBL] [Abstract][Full Text] [Related]
31. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
32. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study.
Rauf SM; Ismael M; Sahu KK; Suzuki A; Koyama M; Tsuboi H; Hatakeyama N; Endou A; Takaba H; Del Carpio CA; Kubo M; Miyamoto A
Comput Biol Med; 2010 May; 40(5):498-508. PubMed ID: 20403587
[TBL] [Abstract][Full Text] [Related]
33. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization.
Sun XZ; Vinci C; Makmura L; Han S; Tran D; Nguyen J; Hamann M; Grazziani S; Sheppard S; Gutova M; Zhou F; Thomas J; Momand J
Antioxid Redox Signal; 2003 Oct; 5(5):655-65. PubMed ID: 14580323
[TBL] [Abstract][Full Text] [Related]
34. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.
Brázdová M; Navrátilová L; Tichý V; Němcová K; Lexa M; Hrstka R; Pečinka P; Adámik M; Vojtesek B; Paleček E; Deppert W; Fojta M
PLoS One; 2013; 8(3):e59567. PubMed ID: 23555710
[TBL] [Abstract][Full Text] [Related]
35. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
Calhoun S; Daggett V
Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
[TBL] [Abstract][Full Text] [Related]
36. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
Joerger AC; Ang HC; Veprintsev DB; Blair CM; Fersht AR
J Biol Chem; 2005 Apr; 280(16):16030-7. PubMed ID: 15703170
[TBL] [Abstract][Full Text] [Related]
37. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
38. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.
Balourdas DI; Markl AM; Krämer A; Settanni G; Joerger AC
Cell Death Dis; 2024 Jun; 15(6):408. PubMed ID: 38862470
[TBL] [Abstract][Full Text] [Related]
39. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant.
Barakat K; Issack BB; Stepanova M; Tuszynski J
PLoS One; 2011; 6(11):e27651. PubMed ID: 22110706
[TBL] [Abstract][Full Text] [Related]
40. How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM; Siu WY; Lau A; Poon RY
Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
